Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has received an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $53.61.

GMAB has been the subject of several analyst reports. Truist Financial restated a “buy” rating and issued a $67.00 target price (up from $45.00) on shares of Genmab A/S in a research note on Thursday. JPMorgan Chase & Co. raised shares of Genmab A/S from a “neutral” rating to an “overweight” rating in a report on Monday, October 26th. TD Cowen increased their price target on shares of Genmab A/S from $43.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, October 26th. HC Wainwright raised their price objective on shares of Genmab A/S from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Morgan Stanley boosted their price objective on shares of Genmab A/S from $42.00 to $57.00 and gave the company an “equal weight” rating in a research note on Friday.

Genmab A/S News Roundup

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported that its cancer drug reduced the risk of death by 50% in a head-and-neck cancer trial and met the study’s primary goals. The results could strengthen the drug’s commercial prospects and support potential changes to treatment standards. Genmab drug cuts death risk 50% in head and neck cancer trial
• Positive Sentiment: Analysts raised their valuation expectations: Guggenheim increased its price target to $80 from $58 and maintained a Buy rating; Morgan Stanley raised its target to $57 from $42 while retaining an Equal Weight rating; and Goldman Sachs initiated or reiterated a Buy recommendation. Guggenheim analyst recommendation Genmab receives a Buy from Goldman Sachs
• Positive Sentiment: Truist reaffirmed its Buy rating and lifted its target to $67 from $45, while HC Wainwright raised its target to $70 from $50. HC Wainwright also maintained a Buy rating, suggesting analysts see additional upside despite the recent rally. HC Wainwright analyst recommendation
• Positive Sentiment: Coverage describing Genmab as potentially undervalued after its trial successes adds to the bullish narrative around the company’s pipeline and long-term growth prospects. Can Genmab still be undervalued after its trial wins?

Genmab A/S Price Performance

GMAB opened at $57.06 on Monday. The company has a market capitalization of $35.61 billion, a price-to-earnings ratio of 44.93, a PEG ratio of 2.26 and a beta of 0.81. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81. The firm has a 50-day moving average price of $37.12 and a 200-day moving average price of $30.58. Genmab A/S has a twelve month low of $23.62 and a twelve month high of $59.97.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.12 billion. Equities analysts expect that Genmab A/S will post 1.22 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Several large investors have recently added to or reduced their stakes in GMAB. Renaissance Technologies LLC lifted its position in Genmab A/S by 26.4% during the first quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company’s stock valued at $118,442,000 after purchasing an additional 921,700 shares during the last quarter. First Trust Advisors LP grew its stake in Genmab A/S by 84.3% in the 1st quarter. First Trust Advisors LP now owns 2,461,342 shares of the company’s stock worth $66,038,000 after buying an additional 1,126,069 shares in the last quarter. Quantinno Capital Management LP grew its stake in Genmab A/S by 14.4% in the 1st quarter. Quantinno Capital Management LP now owns 282,498 shares of the company’s stock worth $7,579,000 after buying an additional 35,588 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Genmab A/S by 1.8% in the 1st quarter. Royal Bank of Canada now owns 150,135 shares of the company’s stock worth $4,029,000 after buying an additional 2,637 shares during the last quarter. Finally, Legacy Wealth Asset Management LLC increased its holdings in shares of Genmab A/S by 164.1% in the 2nd quarter. Legacy Wealth Asset Management LLC now owns 102,164 shares of the company’s stock worth $2,806,000 after buying an additional 63,484 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.